December 02, 2020
Home  »  Website  »  International  »  COVID-19 Vaccine Trial Will Continue, Says Oxford After Participant’s Death

COVID-19 Vaccine Trial Will Continue, Says Oxford After Participant’s Death

The Oxford vaccine is being developed in conjunction with the international pharmaceutical company AstraZeneca.

Google + Linkedin Whatsapp
Follow Outlook India On News
COVID-19 Vaccine Trial Will Continue, Says Oxford After Participant’s Death
Representational Image/Unsplash
COVID-19 Vaccine Trial Will Continue, Says Oxford After Participant’s Death
outlookindia.com
2020-10-22T18:10:09+05:30

The University of Oxford says the late-stage trial of its COVID-19 vaccine in Brazil will continue following reports of a participant's death.

The university said it can't comment on specific incidents but an independent review found no reason to be concerned about the safety of the Brazilian trial.

It says an “independent review, in addition to the Brazilian regulator, have recommended that the trial should continue.”

The Oxford vaccine is being developed in conjunction with the international pharmaceutical company AstraZeneca. Trials are underway in the United States and the UK, as well as Brazil, to determine whether the potential vaccine is safe and effective in humans.


For in-depth, objective and more importantly balanced journalism, Click here to subscribe to Outlook Magazine
Next Story >>
Google + Linkedin Whatsapp

The Latest Issue

Outlook Videos